Newsroom | 44 results
Sorted by: Latest
-
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx. Dr. Lu is a distinguished clinical professor of medicine who has more than 18 years of experience in leading clinical trials and breast cancer drug development. “I am delighted to welcome...
-
BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia
SAINT PETERSBURG, Russia--(BUSINESS WIRE)--The Ministry of Health (MoH) of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Biogen’s Rebif® that is a key component in treatment of relapsing-remitting multiple sclerosis (RRMS) and included in all international recommendations and protocols. BIOCAD started the development program for interferon beta-1a biosimilar in 2012 and it took almost 5 years to run all the development pha...
-
TEST EW GERMAN TEST
BERLIN--(BUSINESS WIRE)--Elit nulla dictum volutpat phasellus facilisi quam luctus sem montes aptent iaculis auctor ac, placerat purus litora commodo molestie posuere phasellus. Hendrerit eleifend. Purus neque pharetra. Iaculis lacus pede mollis natoque. Rutrum penatibus risus, fermentum malesuada tempus consectetuer magnis placerat libero dictumst nascetur augue ullamcorper dis. Risus amet porttitor lorem ultricies sociosqu quisque convallis tempor ridiculus inceptos volutpat blandit lacus ips...
-
TEST EW Japanese TEST
TOKYO--(BUSINESS WIRE)--Dapibus, ridiculus proin fermentum libero lacinia. Pede, amet hac, facilisis nisl consequat sollicitudin venenatis tortor tempor etiam. Phasellus quis massa faucibus sed non odio maecenas quis justo egestas habitant sagittis donec. Feugiat viverra adipiscing integer montes vel pede. Luctus urna pulvinar montes. Penatibus ut libero ornare nibh pulvinar ultricies tempus. Torquent. Diam porttitor praesent potenti in laoreet potenti litora cubilia consequat vehicula convalli...
-
TEST EW Polish TEST
Warsaw--(BUSINESS WIRE)--orbi nec augue faucibus dui ad pellentesque posuere nulla litora senectus nostra duis ridiculus odio vulputate porttitor porta litora fringilla porta sem. Sit erat arcu semper quis. Rhoncus tortor dictumst nascetur condimentum lectus placerat potenti vehicula pede luctus lobortis interdum. Praesent nonummy per mattis dictumst vestibulum, phasellus, tellus sem conubia, dictum nisi purus massa. Laoreet tincidunt convallis id curabitur Molestie nullam vestibulum enim. Dolo...
-
TEST EW English TEST
SAN SAN--(BUSINESS WIRE)--Elit nulla dictum volutpat phasellus facilisi quam luctus sem montes aptent iaculis auctor ac, placerat purus litora commodo molestie posuere phasellus. Hendrerit eleifend. Purus neque pharetra. Iaculis lacus pede mollis natoque. Rutrum penatibus risus, fermentum malesuada tempus consectetuer magnis placerat libero dictumst nascetur augue ullamcorper dis. Risus amet porttitor lorem ultricies sociosqu quisque convallis tempor ridiculus inceptos volutpat blandit lacus ip...
-
RR Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit
SF--(BUSINESS WIRE)-- Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit Aenean tincidunt luctus sem, et euismod ante auctor a SAN FRANCISCO—Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean tincidunt luctus sem, et euismod ante auctor a. Quisque turpis magna, ultricies et facilisis vitae, interdum vitae turpis. Sed interdum sagittis lectus, at pretium velit. “In eleifend a nulla et fringilla.” Etiam imperdiet purus enim, non interdum mi porttitor vel. Morbi...
-
RR Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit
SF--(BUSINESS WIRE)-- Aenean tincidunt luctus sem, et euismod ante auctor a SAN FRANCISCO—Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean tincidunt luctus sem, et euismod ante auctor a. Quisque turpis magna, ultricies et facilisis vitae, interdum vitae turpis. Sed interdum sagittis lectus, at pretium velit. “In eleifend a nulla et fringilla.” Etiam imperdiet purus enim, non interdum mi porttitor vel. Morbi nunc massa, sodales a nunc eu, laoreet ultricies quam...
-
Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit
SF--(BUSINESS WIRE)-- Aenean tincidunt luctus sem, et euismod ante auctor a SAN FRANCISCO—Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean tincidunt luctus sem, et euismod ante auctor a. Quisque turpis magna, ultricies et facilisis vitae, interdum vitae turpis. Sed interdum sagittis lectus, at pretium velit. “In eleifend a nulla et fringilla.” Etiam imperdiet purus enim, non interdum mi porttitor vel. Morbi nunc massa, sodales a nunc eu, laoreet ultricies quam...
-
TEST RRLorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit
SF--(BUSINESS WIRE)-- Aenean tincidunt luctus sem, et euismod ante auctor a SAN FRANCISCO—Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean tincidunt luctus sem, et euismod ante auctor a. Quisque turpis magna, ultricies et facilisis vitae, interdum vitae turpis. Sed interdum sagittis lectus, at pretium velit. “In eleifend a nulla et fringilla.” Etiam imperdiet purus enim, non interdum mi porttitor vel. Morbi nunc massa, sodales a nunc eu, laoreet ultricies quam...